Screening for Prostate Cancer Starting at Age 50–54 Years. A Population-based Cohort Study-Reference-Cited by-同舟云学术

Screening for Prostate Cancer Starting at Age 50–54 Years. A Population-based Cohort Study

Published:2017-01 Issue:1 Volume:71 Page:46-52
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Carlsson Sigrid,Assel Melissa,Ulmert David,Gerdtsson Axel,Hugosson Jonas,Vickers Andrew,Lilja Hans

Publisher

Elsevier BV

Subject

Urology

Reference27 articles.

1. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement;Moyer;Ann Intern Med,2012

2. Early detection of prostate cancer: European Association of Urology recommendation;Heidenreich;Eur Urol,2013

3. Early detection of prostate cancer: AUA Guideline;Carter;J Urol,2013

4. National Comprehensive Cancer Network prostate cancer screening guidelines Version 1. 2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf.

5. The Memorial Sloan Kettering Cancer Center recommendations for prostate cancer screening;Vickers;Urology,2016

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort;European Urology Oncology;2024-07

2. Prediagnostic Prostate-specific Antigen Testing and Clinical Characteristics in Men with Lethal Prostate Cancer;European Urology Open Science;2024-04

3. Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review;BJUI Compass;2024-02-09

4. Application and optimization of prostate-specific antigen screening strategy in the diagnosis of prostate cancer: a systematic review;Frontiers in Oncology;2024-01-09

5. Prostate Specific Antigen Screening on a Nationwide Level: Featuring the Contribution of Race and Life Expectancy in Decision Making;Clinical Genitourinary Cancer;2023-11